Tags

Type your tag names separated by a space and hit enter

Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study.
Br J Nutr 2009; 102(7):1065-74BJ

Abstract

Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of ninety-three overweight or obese subjects aged 25-65 years with metabolic syndrome traits. Subjects were randomised to receive 150 mg quercetin/d in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 5-week washout period. Mean fasting plasma quercetin concentrations increased from 71 to 269 nmol/l (P < 0.001) during quercetin treatment. In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2.6 mmHg (P < 0.01) in the entire study group, by 2.9 mmHg (P < 0.01) in the subgroup of hypertensive subjects and by 3.7 mmHg (P < 0.001) in the subgroup of younger adults aged 25-50 years. Quercetin decreased serum HDL-cholesterol concentrations (P < 0.001), while total cholesterol, TAG and the LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios were unaltered. Quercetin significantly decreased plasma concentrations of atherogenic oxidised LDL, but did not affect TNF-alpha and C-reactive protein when compared with placebo. Quercetin supplementation had no effects on nutritional status. Blood parameters of liver and kidney function, haematology and serum electrolytes did not reveal any adverse effects of quercetin. In conclusion, quercetin reduced SBP and plasma oxidised LDL concentrations in overweight subjects with a high-CVD risk phenotype. Our findings provide further evidence that quercetin may provide protection against CVD.

Authors+Show Affiliations

Institute of Human Nutrition and Food Science, Department of Human Nutrition, Christian-Albrechts-University Kiel, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19402938

Citation

Egert, Sarah, et al. "Quercetin Reduces Systolic Blood Pressure and Plasma Oxidised Low-density Lipoprotein Concentrations in Overweight Subjects With a High-cardiovascular Disease Risk Phenotype: a Double-blinded, Placebo-controlled Cross-over Study." The British Journal of Nutrition, vol. 102, no. 7, 2009, pp. 1065-74.
Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr. 2009;102(7):1065-74.
Egert, S., Bosy-Westphal, A., Seiberl, J., Kürbitz, C., Settler, U., Plachta-Danielzik, S., ... Müller, M. J. (2009). Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. The British Journal of Nutrition, 102(7), pp. 1065-74. doi:10.1017/S0007114509359127.
Egert S, et al. Quercetin Reduces Systolic Blood Pressure and Plasma Oxidised Low-density Lipoprotein Concentrations in Overweight Subjects With a High-cardiovascular Disease Risk Phenotype: a Double-blinded, Placebo-controlled Cross-over Study. Br J Nutr. 2009;102(7):1065-74. PubMed PMID: 19402938.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. AU - Egert,Sarah, AU - Bosy-Westphal,Anja, AU - Seiberl,Jasmin, AU - Kürbitz,Claudia, AU - Settler,Uta, AU - Plachta-Danielzik,Sandra, AU - Wagner,Anika E, AU - Frank,Jan, AU - Schrezenmeir,Jürgen, AU - Rimbach,Gerald, AU - Wolffram,Siegfried, AU - Müller,Manfred J, Y1 - 2009/04/30/ PY - 2009/5/1/entrez PY - 2009/5/1/pubmed PY - 2009/12/16/medline SP - 1065 EP - 74 JF - The British journal of nutrition JO - Br. J. Nutr. VL - 102 IS - 7 N2 - Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of ninety-three overweight or obese subjects aged 25-65 years with metabolic syndrome traits. Subjects were randomised to receive 150 mg quercetin/d in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 5-week washout period. Mean fasting plasma quercetin concentrations increased from 71 to 269 nmol/l (P < 0.001) during quercetin treatment. In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2.6 mmHg (P < 0.01) in the entire study group, by 2.9 mmHg (P < 0.01) in the subgroup of hypertensive subjects and by 3.7 mmHg (P < 0.001) in the subgroup of younger adults aged 25-50 years. Quercetin decreased serum HDL-cholesterol concentrations (P < 0.001), while total cholesterol, TAG and the LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios were unaltered. Quercetin significantly decreased plasma concentrations of atherogenic oxidised LDL, but did not affect TNF-alpha and C-reactive protein when compared with placebo. Quercetin supplementation had no effects on nutritional status. Blood parameters of liver and kidney function, haematology and serum electrolytes did not reveal any adverse effects of quercetin. In conclusion, quercetin reduced SBP and plasma oxidised LDL concentrations in overweight subjects with a high-CVD risk phenotype. Our findings provide further evidence that quercetin may provide protection against CVD. SN - 1475-2662 UR - https://www.unboundmedicine.com/medline/citation/19402938/Quercetin_reduces_systolic_blood_pressure_and_plasma_oxidised_low_density_lipoprotein_concentrations_in_overweight_subjects_with_a_high_cardiovascular_disease_risk_phenotype:_a_double_blinded_placebo_controlled_cross_over_study_ L2 - https://www.cambridge.org/core/product/identifier/S0007114509359127/type/journal_article DB - PRIME DP - Unbound Medicine ER -